Cross-sectional studies have revealed that COPD patients aged 40 years or older who consistently consumed 0.5 g of n-3 LC-PUFAs daily for 6 months exhibited increased 6-min walk test distances and quality of life, along with reduced disease exacerbation frequency, bronchodilator use, and serum C-reactive protein (CRP) levels [61]. Here, CRP is linked to chronic obstructive pulmonary disease.